XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($) $ in Thousands |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Jul. 30, 2013 | Sep. 30, 2016 | Jun. 30, 2016 | Dec. 31, 2015 | Jun. 30, 2015 | Sep. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Deferred revenue, net of current |  | $ 104,636 |  | $ 85,132 |  | $ 104,636
AstraZeneca Agreements [Member] | U.S./RoW [Member] |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Expected upfront, non-contingent and time-based payments | $ 374,000 |  |  |  |  |
Upfront, non-contingent and time-based payments received |  |  | $ 62,000 |  |  |
Development and regulatory approval milestones | 550,000 |  |  |  |  |
Commercial sales milestone | 325,000 |  |  |  |  |
Shared development costs |  |  |  | 233,000 |  |
Additional consideration based on net sales description |  |  |  |  |  | Low 20% range
AstraZeneca Agreements [Member] | U.S./RoW [Member] | FibroGen, Inc. [Member] |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Shared development costs |  |  |  | $ 116,500 |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Development Milestones [Member] |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Receipt of development milestone payment |  |  |  |  | $ 15,000 |
AstraZeneca Agreements [Member] | China [Member] |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Development and regulatory approval milestones | 161,000 |  |  |  |  |
Commercial sales milestone | 167,500 |  |  |  |  |
Proceeds from upfront payments | 28,200 |  |  |  |  |
Contingent payment | $ 20,000 |  |  |  |  |
Estimated joint development service period |  | 2018 |  |  |  |
Estimated joint development extended service period |  | 2020 |  |  |  |
Deferred revenue, net of current |  | $ 7,100 |  |  |  | $ 7,100

X
- Definition The amount of additional consideration based on net sales of product as defined under a collaboration agreement. + References No definition available. + Details
Name: | fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_CommercialSalesMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of contingent payments provided for under the collaboration agreement. + References No definition available. + Details
Name: | fgen_ContingentPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement. + References No definition available. + Details
Name: | fgen_DevelopmentAndRegulatoryApprovalMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development milestone payment received. + References No definition available. + Details
Name: | fgen_DevelopmentMilestonePaymentReceived
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Estimated joint development extended service period. + References No definition available. + Details
Name: | fgen_EstimatedJointDevelopmentExtendedServicePeriod
Namespace Prefix: | fgen_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Estimated joint development service period. + References No definition available. + Details
Name: | fgen_EstimatedJointDevelopmentServicePeriod
Namespace Prefix: | fgen_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the total amount of expected non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ExpectedProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the total amount of development costs that will be shared under collaborative agreement. + References No definition available. + Details
Name: | fgen_SharedDevelopmentCosts
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(c).Q3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q1(c)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q2) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=fgen_FibroGenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |